NASDAQ:ACER Acer Therapeutics (ACER) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free ACER Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.66▼$0.8550-Day Range$0.66▼$0.9052-Week Range$0.55▼$4.56Volume574,600 shsAverage VolumeN/AMarket Capitalization$16.15 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Acer Therapeutics alerts: Email Address Acer Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside127.2% Upside$1.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.35Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.45 out of 5 stars 3.0 Analyst's Opinion Consensus RatingAcer Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAcer Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ACER. Previous Next 0.0 Dividend Strength Dividend YieldAcer Therapeutics does not currently pay a dividend.Dividend GrowthAcer Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACER. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Acer Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for ACER on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acer Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.40% of the stock of Acer Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Acer Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acer Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Acer Therapeutics Stock (NASDAQ:ACER)Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. ACER Stock News HeadlinesApril 26, 2024 | msn.comCrews responding to structure fire on Spruill AvenueApril 26, 2024 | msn.comFBI was scene of incident in Portsmouth on Broomhill AvenueApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 26, 2024 | msn.comKohr Explores: 82nd Avenue of Roses Parade takes to the streets SaturdayApril 26, 2024 | msn.comNorth Avenue closureApril 26, 2024 | msn.comFire crews on the scene of Denby Avenue structure fireApril 25, 2024 | msn.comMan killed in hit-and-run on Jackson AvenueMarch 28, 2024 | uk.finance.yahoo.comZevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ...April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 22, 2024 | msn.comHow to score 50% off The Legend of Zelda: Breath of the WildJanuary 6, 2024 | benzinga.comAcer Therapeutics Inc Stock (OTC:ACER), Guidance and ForecastJanuary 6, 2024 | benzinga.comAcer Therapeutics Inc Stock (OTC:ACER) Dividends: History, Yield and DatesJanuary 4, 2024 | finance.yahoo.comZevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical OfficerDecember 31, 2023 | morningstar.comRelief Therapeutics Holding SA RLFNovember 18, 2023 | benzinga.comAcer Therapeutics Stock (NASDAQ:ACER) Insider TradesNovember 7, 2023 | markets.businessinsider.comZevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsNovember 1, 2023 | sg.finance.yahoo.comAcer Therapeutics Inc. (ACER)September 6, 2023 | 247wallst.comHC Wainwright Downgrades Acer TherapeuticsSeptember 5, 2023 | 247wallst.comRoth MKM Downgrades Acer TherapeuticsSeptember 5, 2023 | msn.comZevra's Rare Find: Unearthing Value In Niche Rare Diseases The Market OverlooksSeptember 2, 2023 | msn.comRoth Capital Downgrades Acer Therapeutics (ACER)September 2, 2023 | msn.comRoth MKM Downgrades Acer Therapeutics (ACER)September 1, 2023 | msn.comAcer (ACER) to Get Acquired by Zevra for $91M, Stock UpSeptember 1, 2023 | msn.comAcer Therapeutics will reacquire OLPRUVA rights from Relief TherapeuticsAugust 31, 2023 | marketwatch.comZevra Therapeutics to Buy Acer Therapeutics >ZVRA ACERSee More Headlines Receive ACER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACER CUSIPN/A CIK1069308 Webwww.acertx.com Phone(844) 902-6100Fax281-872-8585Employees30Year Founded2013Price Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+127.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,240,000.00 Net MarginsN/A Pretax Margin-13,034.14% Return on EquityN/A Return on Assets-9.95% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.02 Sales & Book Value Annual Sales$1.26 million Price / Sales12.81 Cash FlowN/A Price / Cash FlowN/A Book Value($1.05) per share Price / Book-0.63Miscellaneous Outstanding Shares24,460,000Free Float19,963,000Market Cap$16.15 million OptionableNot Optionable Beta0.21 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Christopher Schelling (Age 47)Founder, President, CEO & Director Comp: $739.82kMr. Harry S. Palmin (Age 53)Chief Financial Officer Comp: $545.36kDr. Adrian Quartel FFPM (Age 56)M.D., Chief Medical Officer Comp: $421.65kMs. Tanya Hayden (Age 43)Chief Operating Officer Mr. John Michael Klopp (Age 48)Chief Technical Officer Mr. Donald R. Joseph J.D. (Age 69)Chief Legal Officer & Secretary Comp: $490.28kMr. Bernie Paul (Age 64)Chief People Officer Mr. Jefferson E. Davis (Age 56)Chief Business Officer Comp: $326.67kMr. Jason Kneeland CPAVP of Finance & ControllerMore ExecutivesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors ACER Stock Analysis - Frequently Asked Questions Should I buy or sell Acer Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACER, but not buy additional shares or sell existing shares. View ACER analyst ratings or view top-rated stocks. What is Acer Therapeutics' stock price target for 2024? 3 analysts have issued 12 month target prices for Acer Therapeutics' shares. Their ACER share price targets range from $1.50 to $1.50. On average, they expect the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 127.2% from the stock's current price. View analysts price targets for ACER or view top-rated stocks among Wall Street analysts. How were Acer Therapeutics' earnings last quarter? Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings results on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.05. What is Jason Chen's approval rating as Acer Therapeutics' CEO? 64 employees have rated Acer Therapeutics Chief Executive Officer Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among the company's employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acer Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO). Does Acer Therapeutics have any subsidiaries? The following companies are subsidiares of Acer Therapeutics: Opexa Therapeutics Inc..Read More This page (NASDAQ:ACER) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acer Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.